All stock lists
Basel Medical Group Ltd (NASDAQ:BMGL)
SG · Delayed Price · Currency is USD
Healthcare · Medical - Care Facilities
1.93-3.47 (-64.26%)
Market cap
$3.05M
Insider Score
Health Score
Listed since
Feb 25, 2025
Website
Insider Score
––Not scored
BMGL Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Weak
From BMGL’s reported statements · Q2 2026 (trailing 12 months)
Profitability9 / 20
Loses money on what it sells.
- Revenue
- $25.5M
- Net income
- -$614K
- Net margin
- -2.4%
Leverage1 / 20
Heavily indebted for what it earns.
- Total debt
- $9.6M
- Cash
- $530K
- Debt / equity
- 1.90
Liquidity10 / 20
Covers near-term obligations, without much room.
- Current assets
- $12.1M
- Current liabilities
- $9.9M
- Current ratio
- 1.23
Cash generation8 / 20
Roughly cash-neutral.
- Operating cash flow
- -$1.4M
- Free cash flow
- -$1.8M
- FCF margin
- -6.9%
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 1.1M
- Share growth (1y)
- -94.2%
- Cash runway
- 4 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
BMGL Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 6.55 M | 6.55 M | 8.24 M | 4.21 M | 6.05 M | 3.16 M |
| Revenue Growth (YoY) | 8.10 % | 107.32 % | 226.91 % | — | — | — |
| Cost of Revenue | 2.78 M | 2.78 M | 9.22 M | 3.81 M | 5.41 M | 2.53 M |
| Gross Profit | 3.77 M | 3.77 M | -983.32 K | 401.61 K | 644.32 K | 630.35 K |
| SG&A Expense | 1.11 K | 1.11 K | 1.93 M | 2.23 K | 2.26 M | 10.54 K |
| R&D Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.11 K | 1.11 K | 1.93 M | 2.23 K | 2.26 M | 10.54 K |
| Operating Income | 3.77 M | 3.77 M | -2.91 M | 399.39 K | -1.61 M | 619.81 K |
| Pretax Income | -793.09 K | -793.09 K | 335.24 K | 168.17 K | -10.34 M | -5.37 M |
| Tax Provision | 1.84 K | 1.84 K | 175.31 K | 87.94 K | -402.41 K | 208.89 K |
| Net Income | -508.66 K | -508.66 K | 268.44 K | 134.66 K | -9.94 M | -5.16 M |
| EPS (Basic) | -0.64 | -0.32 | 0.17 | 0.09 | -0.52 | -2.90 |
| EPS (Diluted) | -0.64 | -0.47 | 0.17 | 0.09 | -0.52 | -2.90 |
| Shares Outstanding | 1.08 M | 1.08 M | 1.57 M | 1.57 M | 18.79 M | 1.78 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.